New drug target identified for multiple sclerosis and Alzheimer's disease

Researchers at Boston University School of Medicine (BUSM) led by Carmela Abraham, PhD, professor of biochemistry, along with Cidi Chen, PhD, and other collaborators, report that the protein Klotho plays an important role in the health of myelin, the insulating material allowing for the rapid communication between nerve cells. These findings, which appear online in Journal of Neuroscience, may lead to new therapies for multiple sclerosis (MS) and Alzheimer's disease (AD), in which white matter abnormalities are also common but have been largely ignored.

MS is an inflammatory disease which damages the fatty around the axons of the brain and spinal cord. This destruction, loss or scarring of the sheaths results in a broad spectrum of symptoms. Disease onset usually occurs in young adults, most commonly women.

In MS the myelin is attacked by the immune system and may not be completely restored by myelin-producing cells (mature oligodendrocytes). The researchers discovered that the addition of Klotho protein to immature oligodendrocytes causes them to mature and manufacture proteins needed for the production of healthy myelin.

"These results taken together indicate that Klotho could become a for multiple sclerosis and other white matter diseases, including AD," explained Abraham.

Abraham and her colleagues have identified, and are working on optimizing, a number of small molecules that could form the basis for the development of therapeutic drugs, which would increase the amount of Klotho protein in the brain.

Since Klotho is not only an age suppressor but also a , as shown by other research groups, interventions with Klotho-enhancing drugs may solve some of the most treatment-resistant human ailments according to Abraham.

Klotho was named after the Greek Goddess and daughter of Zeus, who spins the thread of life. Abraham's lab was the first to publish (in 2008) that Klotho levels in the brain decrease with age.

Related Stories

Anti-aging hormone Klotho may prevent complications

Feb 18, 2011

Low levels of the anti-aging hormone Klotho may serve as an early warning sign of the presence of kidney disease and its deadly cardiovascular complications, according to findings by UT Southwestern Medical Center researchers.

A new treatment for kidney disease-associated heart failure?

Jan 09, 2013

Chronic kidney disease (CKD) patients frequently suffer from mineral bone disorder, which causes vascular calcification and, eventually, chronic heart failure. Similar to patients with CKD, mice with low levels of the protein ...

Multiple sclerosis: Damaged myelin not the trigger

Feb 27, 2012

Damaged myelin in the brain and spinal cord does not cause the autoimmune disease multiple sclerosis (MS), neuroimmunologists from the University of Zurich have now demonstrated in collaboration with researchers from Berlin, ...

Recommended for you

From happiness to pain: Understanding serotonin's function

6 hours ago

In a study published today, in the scientific journal PLoS One, researchers at the Champalimaud Neuroscience Programme establish the effect of serotonin on sensitivity to pain using a combination of advanced genetic and op ...

The striatum acts as hub for multisensory integration

16 hours ago

A new study from Karolinska Institutet in Sweden provides insight on how the brain processes external input such as touch, vision or sound from different sources and sides of the body, in order to select ...

User comments